From biology to personalized medicine: Recent knowledge in osteosarcoma
Audrey Mohr, Maria Eugénia Marques Da Costa, Olivia Fromigué, Baptiste Audinot, Thierno Balde, Robin Droit, Samuel Abbou, Pierre Khneisser, Pablo Berlanga, Esperanza Pérez, Antonin Marchais, Nathalie Gaspar
Abstract
High-grade osteosarcoma is the most common paediatric bone cancer. More than one third of patients relapse and die of osteosarcoma using current chemotherapeutic and surgical strategies. To improve outcomes in osteosarcoma, two crucial challenges need to be tackled: 1-the identification of hard-to-treat disease, ideally from diagnosis; 2- choosing the best combined or novel therapies to eradicate tumor cells which are resistant to current therapies leading to disease dissemination and metastasize as well as their favorable microenvironment. Genetic chaos, tumor complexity and heterogeneity render this task difficult. The development of new technologies like next generation sequencing has led to an improvement in osteosarcoma oncogenesis knownledge. This review summarizes recent biological and therapeutical advances in osteosarcoma, as well as the challenges that must be overcome in order to develop personalized medicine and new therapeutic strategies and ultimately improve patient survival.